Medications Indicated for Chronic Weight Management
This chapter reviews the medications currently available for chronic weight management in the USA and some other countries and, for those five medications, discusses mechanism of action, efficacy data, and safety profiles. The chapter also discusses principles of prescribing and best practices for managing patients with medications indicated for weight management. Four of the newer agents (lorcaserin, liraglutide 3.0 mg, naltrexone SR/ bupropion SR, and phentermine/topiramate ER) all act primarily in the central nervous system. They regulate appetite and reduce food intake to help patients better adhere to a dietary plan. Orlistat acts peripherally to block absorption of 30% of ingested fat and reinforces adherence to a low-fat diet, thus reducing energy intake. These five newer medications are intended for long-term use to help patients not only lose more weight than with lifestyle changes alone, but also to maintain hard-won weight losses. Best practices in chronic disease prevention and management currently require physicians to help patients manage weight as a pathway to health improvement and those patients who struggle with weight and would derive health benefits from weight loss are candidates for medications. A current trend is to intervene earlier with these medications, especially with patients at higher health risk. The available medications have differing profiles in safety, efficacy, and tolerability. No one medication is right for every patient and the patient’s profile must be matched to the medication profile. Thus, providers caring for patients with obesity-associated risk and diseases should be knowledgeable on how to prescribe for chronic weight management. Finally, if patients have success with a medication and lifestyle change to produce weight loss, the medication should be continued to maintain weight loss. Since weight regain is an issue when medications are stopped, restarting medications is also appropriate.
KeywordsObesity pharmacotherapy Weight management Liraglutide Phentermine Phentermine/Topiramate ER Naltrexone SR/Bupropion SR Lorcaserin Orlistat
Supported in part by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”
- Alli™ product label, US Food and Drug Administration. https://www.accessdata.fda.gov/-drugsatfda_docs/label/2007/021887lbl.pdf. Accessed 15 Apr 2017.
- Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD. Endocrine Society. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015a;100(2):342–62. Erratum in: J Clin Endocrinol Metab 2015 May;100(5):2135–6.CrossRefGoogle Scholar
- Belviq® prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs-/label/2012/022529lbl.pdf. Accessed 15 Apr 2017.
- Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical evaluation of medicinal products used in weight management. 23 June 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500209942.pdf. Accessed 15 Apr 2017.
- Contrave® FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed 15 Apr 2017.
- Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.CrossRefGoogle Scholar
- Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.CrossRefGoogle Scholar
- Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical Care of Patients with obesity. Endocr Pract. 2016a;22(7):842–84. Executive Summary. Complete guidelines available at https://www.aace.com/publications/guidelinesCrossRefGoogle Scholar
- Guidance for industry developing products for weight management. Draft Guidance. US Department of Health and Human Services, Food and Drug Administration, February 2007, Revision 1. https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed 15 April 2017.
- Hollander P, Gupta AK, Plodkowski R, et al for the COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.CrossRefGoogle Scholar
- Le Roux CW, Astrup A, Fujioka K, et al for the show SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet. 2016;389(10077):1399–409.Google Scholar
- National Institute for Health and Clinical Excellence: Guidance. Obesity: Identification, Assessment and Management of Overweight and Obesity in Children, Young People and Adults: Partial Update of CG43. National Clinical Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK); 2014.Google Scholar
- Qsymia™ FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/022580s000lbl.pdf. Accessed 15 Apr 2017.
- Saxenda® FDA Advisory Panel Briefing Document. https://www.fda.gov/downloads/advisory committees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisory committee/ucm413317.pdf. Accessed 15 Apr 2017.
- Saxenda® prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs /label/2014/206321Orig1s000lbl.pdf. Accessed 15 Apr 2017.
- Tran PT, Thomas A. Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting March 28–29, 2012. http://www.fda.gov/downloads/AdvisoryCommittees /CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303352.pdf. Accessed 15 Apr 2017.
- Victoza® full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022341s025lbl.pdf. Accessed 15 Apr 2017.
- XENICAL prescribing information, US Food and Drug Administration. https://www.fda.gov/downloads-/UCM205349.pdf. Accessed 15 Apr 2017.